D. E. Shaw & Co., Inc. Altimmune, Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 51,258 shares of ALT stock, worth $204,006. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,258

Previous 50,516 1.47%

Holding current value

$204,006

Previous $252,000 21.43%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.5 - $7.71 $2,597 - $5,720	742 Added 1.47%	51,258 $198,000
Q1 2025 May 15, 2025	SELL	$5.0 - $7.45 $2.05 Million - $3.05 Million	-409,317 Reduced 89.01%	50,516 $252,000
Q4 2024 Feb 14, 2025	SELL	$6.02 - $9.85 $1.79 Million - $2.94 Million	-298,171 Reduced 39.34%	459,833 $3.32 Million
Q3 2024 Nov 14, 2024	SELL	$5.5 - $8.1 $23,969 - $35,299	-4,358 Reduced 0.57%	758,004 $4.65 Million
Q2 2024 Aug 14, 2024	BUY	$5.91 - $10.23 $2.41 Million - $4.17 Million	408,012 Added 115.14%	762,362 $5.07 Million
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $531,209 - $892,457	64,624 Added 22.31%	354,350 $3.61 Million
Q4 2023 Feb 14, 2024	SELL	$2.14 - $11.62 $943,752 - $5.12 Million	-441,006 Reduced 60.35%	289,726 $3.26 Million
Q3 2023 Nov 14, 2023	BUY	$2.4 - $3.45 $543,585 - $781,404	226,494 Added 44.92%	730,732 $1.9 Million
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $1.74 Million - $3.01 Million	504,238 New	504,238 $1.78 Million
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $242,115 - $455,697	27,702 New	27,702 $455,000
Q2 2022 Aug 15, 2022	SELL	$3.94 - $11.77 $3.14 Million - $9.39 Million	-798,053 Reduced 82.47%	169,683 $1.99 Million
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $1.26 Million - $2.02 Million	-213,501 Reduced 18.07%	967,736 $5.89 Million
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $1.96 Million - $2.82 Million	225,799 Added 23.63%	1,181,237 $10.8 Million
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $1.08 Million - $2.15 Million	127,682 Added 15.43%	955,438 $10.8 Million
Q2 2021 Aug 16, 2021	SELL	$9.85 - $16.46 $4.81 Million - $8.03 Million	-488,058 Reduced 37.09%	827,756 $8.15 Million
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $1.55 Million - $2.97 Million	122,120 Added 10.23%	1,315,814 $18.6 Million
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $3.66 Million - $6.64 Million	-467,136 Reduced 28.13%	1,193,694 $13.5 Million
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $16.5 Million - $55.2 Million	1,660,830 New	1,660,830 $21.9 Million
Q3 2019 Nov 14, 2019	SELL	$1.95 - $2.66 $23,985 - $32,718	-12,300 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$2.19 - $3.4 $1,752 - $2,720	-800 Reduced 6.11%	12,300 $29,000
Q4 2018 Feb 14, 2019	BUY	$1.72 - $7.24 $22,532 - $94,844	13,100 New	13,100 $27,000

Others Institutions Holding ALT

# of Institutions

216

Shares Held

36.2M

Call Options Held

4.92M

Put Options Held

4.18M

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $195M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account